Dynamic Analysis of Circulating Tumor DNA to Predict the 1 **Prognosis and Monitor the Treatment Response of Patients** 2 with Metastatic Triple-negative Breast Cancer: a prospective 3 study 4 5 Yajing Chi^{1,2}, Mu Su³, Dongdong Zhou¹, Fangchao Zheng¹, Baoxuan Zhang¹, Ling 6 Qiang¹, Guohua Ren¹, Lihua Song¹, Bing Bu¹, Shu Fang¹, Bo Yu³, Jinxing Zhou³, 7 Jinming Yu^{4#}, Huihui Li^{1#} 8 9 1. Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical 10 University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. 11 2. School of Medicine, Nankai University, Tianjin, China 12 3. Department of Bioinformatics, Berry Oncology Corporation, Beijing, China. 13 4. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University 14 and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China. 15 [#]Corresponding author: 16 Huihui Li, Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First 17 Medical University and Shandong Academy of Medical Sciences, No.440, Jiyan Road, Huaiyin District, Jinan, 18 Shandong Province, China, Zip: 250017, Tel: +86 15553103209, Email: huihuili82@163.com. 19 Jinming Yu, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical 20 University and Shandong Academy of Medical Sciences, Jinan, 250017, Shandong Province, China. Email: 21 sdyujinming@163.com. Abstract 22 Background: Limited data are available on the application of circulating tumor DNA 23 (ctDNA) in metastatic triple-negative breast cancer (mTNBC) patients. Here, we 24 investigated the value of ctDNA for predicting the prognosis and monitoring the 25 treatment response in mTNBC patients. 26 Methods: We prospectively enrolled 70 Chinese patients with mTNBC who had 27 progressed after ≤ 2 lines of chemotherapy and collected blood samples to extract 28 ctDNA for 457-gene targeted panel sequencing. 29 30 Results: Patients with ctDNA+, defined by 12 prognosis-relevant mutated genes, had a shorter progression-free survival (PFS) than ctDNA- patients (5.16 months vs. 9.05 31 months, P = 0.001) and ctDNA+ was independently associated with a shorter PFS (HR, 32 95%CI: 2.67, 1.2–5.96; P = 0.016) by multivariable analyses. Patients with a higher 33 34 NOTENTHERpice Aldobe dumor bestor oganes tro (Ada Tili) sogre (206 Saho) rous de geres of Did chrast pour ice. 1

(ctDNA% ≥ 0.05) had a significantly shorter PFS than patients with a lower MATH 35 score (5.67 months vs.11.27 months, P = 0.007) and patients with a lower ctDNA% 36 (5.45 months vs. 12.17 months, P < 0.001), respectively. Positive correlations with 37 treatment response were observed for MATH score (R = 0.24, P = 0.014) and ctDNA% 38 (R = 0.3, P = 0.002), but not the CEA, CA125, or CA153. Moreover, patients who 39 remained ctDNA+ during dynamic monitoring tended to have a shorter PFS than those 40 who did not (3.90 months vs. 6.10 months, P = 0.135). 41 Conclusions: ctDNA profiling provides insight into the mutational landscape of 42

- mTNBC and may reliably predict the prognosis and treatment response of mTNBCpatients.
- Funding: This work was supported by the National Natural Science Foundation of
 China (Grant No. 81902713), Natural Science Foundation of Shandong Province (Grant
 No. ZR2019LZL018), Breast Disease Research Fund of Shandong Provincial Medical
 Association (Grant No. YXH2020ZX066), the Start-up Fund of Shandong Cancer
 Hospital (Grant No. 2020-PYB10), Beijing Science and Technology Innovation Fund
 (Grant No. KC2021-ZZ-0010-1).
 Keywords: Circulating tumor DNA; metastatic triple-negative breast cancer; next-
- 52 generation sequencing; prognosis; treatment response
- 53

54 Introduction

55 Breast cancer is the most common malignant tumor and the leading cause of cancerrelated deaths in women worldwide(Sung et al., 2021). Triple-negative breast cancer 56 (TNBC) represents 15%–20% of all breast cancer cases and exhibits a more aggressive 57 phenotype (with a poorer prognosis) than non-TNBC(Foulkes, Smith, & Reis-Filho, 58 2010; X. Li et al., 2017; Malorni et al., 2012). Due to the absence of human epidermal 59 growth factor receptor 2 (HER2), estrogen receptor (ER), or progesterone receptor (PR) 60 expression, TNBC lacks effective targeted therapies and treatment regimens. Patients 61 with mTNBC have fewer available treatment options and exhibit worse survival than 62 63 early-stage TNBC patients. Furthermore, TNBC is a highly heterogeneous disease, resulting in substantial differences in the tumorigenesis, treatment response, and disease progression among patients(Burstein et al., 2015; Jiang et al., 2019; Perou, 2011), which undoubtedly poses great challenges in prognostic prediction of the mTNBC and efficacy assessment for already limited treatment options. Unfortunately, reliable and tailored biomarkers to predict the prognosis and monitor the treatment response of patients with TNBC are yet to be established.

It has been a long-standing clinical management model to predict the prognosis of 70 patients with mTNBC and guide treatment decision-making through imaging 71 72 examination and mutational features obtained by tumor biopsy. Imaging usually only provides the external characterization of the tumor, but can not reveal tumor internal 73 molecular characteristics. Given the heterogeneity of TNBC, it is not possible to obtain 74 an accurate and comprehensive picture of the mutational landscape using tissue biopsies 75 76 unless repeated multiple biopsies(Diaz & Bardelli, 2014), and most patients are refractory to repetitive punctures. 77

Compared with tissue biopsies, "liquid biopsies" collect and analyze tumor-derived 78 substances, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), 79 and exosomes (e.g., from the blood, cerebrospinal fluid, and urine) of cancer patients 80 in a minimally invasive fashion(Alix-Panabières & Pantel, 2016; Palmirotta et al., 2018; 81 Poulet, Massias, & Taly, 2019). It can be used for early diagnosis of tumor patients, 82 predicting tumor recurrence and metastasis, and evaluating the characteristics and 83 clonal evolution of tumor genomes. ctDNA is a specific fraction of cell-free DNA 84 (cfDNA), which is present in the plasma of apoptotic and necrotic tumor cells(Swarup 85 & Rajeswari, 2007). Owing to special biological origin and the potential for multiple 86 repeat sampling, ctDNA is independent of tumor spatial and temporal heterogeneity, 87 convey more valuable information than a conventional tumor biopsy and enable the 88 89 dynamic monitoring of tumor burden and treatment response(Campos-Carrillo et al., 2020; Chae & Oh, 2019; Dawson et al., 2013; Gerratana et al., 2021). The value of 90 ctDNA in the accurate prediction of drug resistance and clinical outcomes has also been 91 92 noted(Asante, Calapre, Ziman, Meniawy, & Gray, 2020; Murtaza et al., 2013).

93 Several studies have demonstrated the prognostic and predictive value of ctDNA for

non-mTNBC during or after (neo)adjuvant therapy(Cavallone et al., 2020; H. Kim et 94 al., 2021; Lin et al., 2021; Ortolan et al., 2021; Riva et al., 2017). Previously, researchers 95 have also been relatively circumscribed concentrated on evaluating specific copy 96 97 number variants (CNVs) or ctDNA-based single mutation or clonal evolution or the ctDNA level to predict the prognosis of mTNBC patients and the efficacy of specific 98 treatment regimens(Barroso-Sousa et al., 2022; Chopra et al., 2020; Collier et al., 2021; 99 Stover et al., 2018; Weber et al., 2021; Wongchenko et al., 2020). Even a study showed 100 that the ctDNA level had no prognostic impact on survival of patients with 101 mTNBC(Madic et al., 2015). A more comprehensive study of the mutational 102 information and related markers embodied in ctDNA as well as a consensus on the 103 predictive role of ctDNA in mTNBC are needed to apply ctDNA in clinical practice. 104

Hence, in this study, we investigated the mutational characteristics of ctDNA and ctDNA-related markers in mTNBC using targeted, capture-based, next-generation sequencing (NGS), which offers rapid identification and high coverage from a small blood sample. We aimed to dynamically and more comprehensively evaluate the value of ctDNA in predicting the prognosis and monitoring the treatment response of patients with mTNBC.

111

112 Methods

113 Study design and sample collection

Between 2018 and 2021, patients with mTNBC who had progressed after ≤ 2 lines of 114 chemotherapy were prospectively enrolled. A 10 mL sample of peripheral blood was 115 collected into an EDTA anticoagulant tube (STRECK Cell-Free DNA BCT®) from 116 patients at different time points (i.e., before treatment, during treatment [treatment cycle 117 3, day 1], and at progression). Within 2 hours of collection, blood samples were 118 centrifuged at $1,600 \times g$ for 10 min at 4 °C to obtain plasma, followed by secondary 119 centrifugation at $16,000 \times g$ for 10 min at 4 °C to obtained peripheral blood cells. 120 Plasma and peripheral blood cells were stored at -80 °C until the extraction of ctDNA 121 122 and genomic DNA (gDNA). Paraffin-embedded primary or metastatic tumor tissues were collected before treatment and stored at room temperature for later use. 123

124

125 DNA extraction and targeted capture-based NGS

ctDNA was extracted from peripheral blood using the QIAamp Circulating Nucleic 126 127 Acid Kit (Qiagen, Germany) while tumor DNA (tDNA) was extracted from the paraffin-embedded tumor tissues using the AllPrep DNA/RNA FFPE Kit (50) (Qiagen, 128 Germany). Normal control gDNA was extracted from white blood cells using the 129 DNeasy Kit (Qiagen, Germany) according to the manufacturer's instructions. The 130 sequencing library was prepared from the ctDNA and tDNA samples using the KAPA 131 DNA Library Preparation Kit (KAPA Biosystems, USA), while the gDNA sequencing 132 library was constructed using the Illumina TruSeq DNA Library Preparation Kit 133 (Illumina, USA). Library concentration was determined using real-time quantitative 134 PCR and the KAPA Library Quantification Kit (KAPA Biosystems, USA). The library 135 136 fragments were then size-selected using agarose gel electrophoresis. A targeted NGS panel of 457 genes (Supplementary Table 1), which are known to be frequently 137 mutated in tumors, was designed to capture the target DNA fragments. Sequencing 138 libraries were loaded onto a NovaSeq 6000 platform (Illumina, USA) with a 150-bp 139 read length in paired-end mode. 140

141

142 Sequencing data analysis

Quality control of the raw sequencing data involved the use of FASTP to trim adapters 143 and remove low-quality sequences(Chen, Zhou, Chen, & Gu, 2018). The clean reads 144 were aligned against the Ensemble GRCh37/hg19 reference genome using BWA 145 software(H. Li & Durbin, 2009). PCR duplications were processed using the gencore 146 tool(Chen et al., 2019) and uniquely mapped reads were generated. The SAMtools suite 147 was used to detect single-nucleotide variants (SNVs), insertions, and deletions(H. Li et 148 al., 2009). CNVs were called using CONTRA(J. Li et al., 2012), with copy number > 149 3 as the threshold of copy number gain and < 1 as the threshold of copy number loss. 150 The maximal tumor somatic variant allelic frequency (max-VAF) describes the highest 151 152 mutated frequency of ctDNA detected in the cfDNA(Maron et al., 2019). The 153 calculation of the ctDNA fraction (ctDNA%) was based on the autosomal somatic allele

fractions. The mutant allele fraction (MAF) and ctDNA% are related as follows: MAF 154 = $(ctDNA \times 1)/([(1 - ctDNA) \times 2] + [ctDNA \times 1]);$ thus, ctDNA = 2/(1/MAF + 1)155 1)(Vandekerkhove et al., 2017). The mutant-allele tumor heterogeneity (MATH) score 156 157 was calculated as the percentage ratio of the width (median absolute deviation [MAD] scaled by a constant factor, so that the expected MAD of a sample from a normal 158 distribution equals the standard deviation) to the center of the distribution of MAFs 159 among the tumor-specific mutated loci; thus, $MATH = 100 \times MAD/median(Mroz \&$ 160 Rocco, 2013). Tumor mutational burden (TMB) was defined as the number of non-161 synonymous somatic mutations per megabase of genome examined(Chalmers et al., 162 163 2017).

164

165 Statistical analysis

166 The longest diameter (mm) of the tumor was measured by examining the radiological images. The response evaluation was carried out according to the Response Evaluation 167 Criteria in Solid Tumors (RECIST) guidelines (version 1.1)(Eisenhauer et al., 2009). 168 The Kaplan-Meier method was used for the survival analyses; median comparison was 169 performed using the log-rank test and hazard ratios (HRs) from the Cox proportional 170 hazards model. The optimal cut-off values for ctDNA%, MATH score, and TMB were 171 determined by the R package "survminer". Progression-free survival (PFS) was defined 172 as the time interval from the initiation of the study to disease progression or death from 173 any cause. Univariate Cox regression was carried out to analyze the mutations related 174 to PFS; only genes mutated in > 5% of the patients were included in the analysis. The 175 correlation between variables was analyzed using the Spearman correlation test and 176 group comparisons were performed using the Wilcoxon rank-sum test. Statistical 177 analysis and data visualization were conducted using R (version 4.0.1). The statistical 178 179 significance was defined as bilateral P < 0.05.

180

181 **Results**

182 Study cohort and sample information

6

A total of 126 patients with mTNBC were included in the study. Fifty-six patients were 183 excluded, comprising 21 patients who had previously been treated with more than two 184 lines of chemotherapy, 16 patients who were treated with combination therapy (e.g., 185 186 chemotherapy with radiotherapy), 11 patients who were lost to follow-up, and 8 patients who failed to be evaluated for efficacy. Finally, 139 plasma samples (baseline samples 187 from 70 patients and dynamic samples from 38/70 patients) from 70 patients and paired 188 tumor tissues from 13 patients were collected and sequenced (Figure 1A, B). The 189 patient baseline characteristics are shown in Table 1. The median age of all patients 190 was 46 (26–75) years. Overall, 82.9% of patients were diagnosed with invasive ductal 191 carcinoma and most of the patients developed visceral metastases at study entry. Table 192 2 shows that all patients received chemotherapy-based treatment with the most common 193 chemotherapy drugs, such as gemcitabine, taxane, or platinum. Eleven patients were 194 195 also treated with immunotherapy. The objective response rate was 38.6%, and 4, 23, 31, and 12 patients had complete response (CR), partial response (PR), stable disease (SD), 196 and progressive disease (PD), respectively. The median PFS (mPFS) for all patients was 197 6.15 months (Supplementary Figure 1A). There was no significant difference in PFS 198 among different treatment lines or regimens (Supplementary Figure 1B-H), although 199 patients treated in the first line had a trend towards improved survival compared with 200 201 those treated in the second and third lines.





Figure 1. Study design and sample collection. (A) Study flowchart. After excluding 82 patients, a total of 70 patients with mTNBC were included in the final analysis. Baseline blood samples were collected from all patients (n = 70) and paired tumor tissues were collected from 13 patients for NGS. (B) Blood-sample-derived ctDNA was dynamically monitored at baseline (yellow), during treatment (green), and at progression (orange) for 38 of the 70 patients. ctDNA, circulating tumor DNA; mTNBC, metastatic triple-negative breast cancer; NGS, next-generation sequencing.

- 209
- 210

211 Table 1. The baseline characteristics in study population.

Characteristics	All patients-no. (%)	Dynamic monitoring patients-no. (%)
	(n=70)	(n=38)
Age (yrs), median (range)	46 (26-75)	47 (27-75)
≤50	45 (64.3)	26 (68.4)
>50	25 (35.7)	12 (31.6)
Histopathologic diagnosis		
Invasive ductal carcinoma	58 (82.9)	29 (76.3)
Other	10 (14.3)	7 (18.4)
NA	2 (2.9)	2 (5.3)
Pathological grade		
I-II	12 (17.1)	10 (26.3)
III	39 (55.7)	20 (52.6)
NA	19 (27.1)	8 (21.1)
Disease stage at initial diagnosis		
I	7 (10.0)	5 (13.2)
II	20 (28.6)	10 (26.3)
III	33 (47.1)	20 (52.6)
IV	7 (10.0)	3 (7.9)
NA	3 (4.3)	0
Disease-free interval (months)		
\leq 12 (including stage IV at initial	23 (32.9)	11 (28.9)
diagnosis)		
>12	47 (67.1)	27 (71.1)
Sites of metastasis		
Visceral	56 (80.0)	33 (86.8)
Non-visceral	14 (20.0)	5 (13.2)
Previous lines of chemotherapy		
during metastatic stage		
0	46 (65.7)	22 (57.9)
1	19 (27.1)	11 (28.9)
2	5 (7.1)	5 (13.2)
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		

223

Table 2. The treatment characteristics and responses of patients.

Treatment characteristics and responses	All patients-no. (%)	Dynamic monitoring patients-no. (%)		
	(n=70)	(n=38)		
Treatment regimens				
Contained gemcitabine + platinum	17 (24.3)	10 (26.3)		
Contained taxane + platinum	16 (22.9)	7 (18.4)		
Contained vinorelbine + platinum	4 (5.7)	1 (2.6)		
Contained taxane but no platinum	22 (31.4)	14 (36.8)		
Other	11 (15.7)	6 (15.8)		
Treatment modalities				
Immunotherapy + chemotherapy	11 (15.7)	6 (15.8)		
Chemotherapy	59 (84.3)	32 (84.2)		
Treatment responses				
CR	4 (5.7)	4 (10.5)		
PR	23 (32.9)	9 (23.7)		
SD	31 (44.3)	18 (47.4)		
PD	12 (17.1)	7 (18.4)		

225

226 Mutation characteristics of patients with mTNBC

227 Plasma samples were obtained from 70 patients with mTNBC before treatment and submitted for targeted NGS. In total, 203 mutated genes were identified using our panel 228 of 457 genes, including 301 missense mutations, 45 frame-shift indels, 16 in-frame 229 indels, 13 splice-site mutations, and 31 stop-gain mutations. The ten most frequently 230 mutated genes were TP53 (69%), PIK3CA (24%), ARID1A (9%), KMT2C (9%), CIC 231 (7%), KMT2D (7%), NOTCH4 (7%), PBRM1 (7%), PTEN (7%), and DNMT3A (6%). 232 In addition, gene CNVs were detected in 351/457 genes, 296 of which showed copy 233 number gain (CNG), 38 showed copy number loss, and 17 had both gain and loss 234 mutations. The most prevalent genes with CNVs were HLA-C (50%), HLA-A (33%), 235 HLA-B (33%), HLA-DRB1 (23%), SPPL3 (21%), BTG2 (19%), C8orf34 (16%), HLA-236 DQA1 (16%), HLA-E (16%), and LTBP1 (16%) (Figure 2A). 237 We also used NGS to evaluate the discrepancy and consistency of genomic 238 239 alterations in ctDNA samples and paired tumor tissues from 13 patients. The mutation 240 frequency in plasma ctDNA was significantly lower than that in the tumor tissues (0.049%

241 $\pm 0.113\%$ vs. $0.168 \pm 0.173\%$, P < 0.001) (Supplementary Figure 2). A total of 115

242 mutations in 85 genes were detected, which included 84 mutations in 63 genes from

243 plasma ctDNA and 81 mutations in 55 genes from tDNA. The number of ctDNA-

244 specific and tDNA-specific mutated genes was 37 in both cases. Hence, the

concordance rate between mutations in ctDNA and tDNA was 98.75% (Figure 2B).





247 Figure 2. Mutation characteristics of patients with mTNBC. (A) The landscape of ctDNA mutations in 70 patients 248 with mTNBC prior to treatment initiation. The patients (n = 70) were divided into four groups (PD, SD, PR, and CR) 249 according to the best treatment response (from left to right). The top half of the figure shows SNVs with a mutation 250 frequency \geq 5%, and the bottom half shows CNVs with a mutation frequency \geq 10%; the different colored rectangles 251 represent different types of variation. (B) Concordance between the genomic alterations in the blood-derived ctDNA 252 and the tissue-derived tDNA. The mutated genes detected in at least two samples are shown here. The concordance rate = shared mutated genes/(all genes × the number of comparisons) × 100% = (1 - [ctDNA-specific and tissue-253 254 specific mutated genes]/[all genes × the number of comparisons]) × $100\% = (1 - [37 + 37]/[457 \times 13]) \times 100\%$ 255 98.75%. CNVs, copy number variants; CR, complete response; ctDNA, circulating tumor DNA; tDNA, tumor DNA;

mTNBC, metastatic triple-negative breast cancer; PD, progressive disease; PR, partial response; SD, stable disease;
 SNVs, single-nucleotide variants.

258

A ctDNA+/- status correlates with the treatment response and survival of patients with mTNBC

Univariate Cox regression analysis showed that 12 mutated genes, including HLA-B 261 (HR, 95% confidence interval [CI]: 1.89, 1.08–3.32), BTG2 (HR, 95% CI: 2.23, 1.15– 262 4.31), MCL1 (HR, 95% CI: 2.31, 1.1–4.84), H3F3A (HR, 95% CI: 2.36, 1.08–5.16), 263 MYC (HR, 95% CI: 3.45, 1.58–7.54), KMT2C (HR, 95% CI: 2.75, 1.14–6.63), KYAT3 264 (HR, 95% CI: 3.66, 1.48–9.04), ARID4B (HR, 95% CI: 4.04, 1.51–10.76), CD22 (HR, 265 95% CI: 3.66, 1.25–10.68), TGFB1 (HR, 95% CI: 3.94, 1.35–11.56), SGK1 (HR, 95% 266 CI: 3.37, 1.15–9.82), and RSPO2 (HR, 95% CI: 4.19, 1.42–12.34), indicated a higher 267 risk for recurrence or progression in patients with mTNBC (Figure 3A). Moreover, 268 these 12 mutated genes were significantly associated with worse survival 269 (Supplementary Figure 3). 270

ctDNA was collected and evaluated at different time points and a plasma ctDNA 271 sample with at least one of the 12 prognosis-relevant mutated genes was defined as 272 ctDNA-positive (ctDNA+) (Figure 3B). The right half of Figure 3B shows that the 273 mPFS in 70 patients with mTNBC was 6.15 months at a median follow-up of 19.13 274 months. As shown, ctDNA+ patients tended to have a shorter survival duration and less 275 276 clinical benefit. At baseline, the ctDNA+ rates were 25%, 43%, 55%, and 33% in patients with CR, PR, SD, and PD, respectively. By comparing the ctDNA+/- status at 277 all the time points, we found that the amount of ctDNA+ positively correlated with a 278 worse treatment response. The proportion of ctDNA+ at different time points was 46% 279 (at baseline), 29% (during treatment), and 44% (at progress), while that in the different 280 treatment response groups was 45% (PD), 39% (SD), 22% (PR), and 0% (CR) (Figure 281 **3C**). Prior to treatment, the tumor size of the ctDNA+ group was significantly larger 282 than that of the ctDNA- group $(52.56 \pm 34.65 \text{ mm } vs. 40.18 \pm 35.49 \text{ mm}, P < 0.001)$ 283 (Figure 3D). We also found that patients who were ctDNA+ at baseline had a shorter 284 285 PFS than those who were ctDNA- at baseline (5.16 months vs. 9.05 months, P = 0.001)

- 286 (Figure 3E). Multivariate Cox regression analysis, which included multiple clinical
- 287 factors and ctDNA status, showed that ctDNA+ was independently associated with a
- 288 shorter PFS (HR, 95% CI: 2.67, 1.2-5.96; P = 0.016) (**Table 3**).





290 Figure 3. Prognostic relevance of mutations in patients with mTNBC. (A) Twelve mutated genes, comprising 291 HLA-B (CNG), BTG2 (CNG), MCL1 (CNG), H3F3A (CNG), MYC (CNG), KMT2C (SNV), KYAT3 (CNG), ARID4B 292 (CNG), CD22 (CNG), TGFB1 (CNG), SGK1 (CNG), and RSPO2 (CNG) were identified as being associated with a 293 higher risk of recurrence or progression in patients with mTNBC (all had HRs > 1 and a P < 0.05). (B) The left half 294 of the figure summarizes the ctDNA status of all patients (n = 70) at different time points; among these, 38 patients 295 also had their ctDNA status recorded during treatment and at progression. Solid dots represent ctDNA+ patients, 296 while unfilled dots represent ctDNA- patients. The length of line segments in the right half of the figure denotes the 297 PFS of patients, whereby the bars indicate the best response (PD, SD, PR, or CR) observed during treatment. (C) 298 Comparison of ctDNA status (ctDNA+, red; ctDNA-, blue) among all the blood samples (n = 139) from patients

299	with different treatment responses (PD, SD, PR, or CR). (D) The tumor size of the ctDNA+ group at baseline was
300	significantly greater than that of the ctDNA- group at baseline. (E) ctDNA+ at baseline was significantly associated
301	with a shorter PFS. CNG, copy number gain; CR, complete response; ctDNA, circulating tumor DNA; ctDNA-,
302	ctDNA negative; ctDNA+, ctDNA positive; HR, hazard ratio; mTNBC, metastatic triple-negative breast cancer; PD,
303	progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; SNV, single-nucleotide
304	variant. A P -value < 0.05 was used as a measure of statistical significance.
305	
306	Table 3. Multivariate cox regression analysis of multiple clinical factors and ctDNA

307 status with PFS of patients.

Variable	HR (95 CI)	p value
Age (≤ 50 vs. > 50 years)	1.21 (0.47-3.1)	0.694
Histopathologic diagnosis (IDC vs. non-IDC)	0.64 (0.15-2.73)	0.55
Pathological grade (III vs. I-II)	1.23 (0.53-2.86)	0.629
DFI (≤ 12 months vs. > 12 nonths)	1.69 (0.6-4.71)	0.319
ctDNA status (ctDNA+ vs. ctDNA-)	2.67 (1.2-5.96)	0.016
T stage (T1 vs. T2 vs. T3)	0.75 (0.38-1.47)	0.397
N stage (N1 vs. N2 vs. N3)	0.79 (0.57-1.1)	0.161
CEA elevation (Yes vs. No)	1.75 (0.64-4.81)	0.278
CA125 elevation (Yes vs. No)	0.67 (0.24-1.88)	0.445
CA153 elevation (Yes vs. No)	1.86 (0.62-5.57)	0.268
Ki-67 (≥ 30% vs. < 30%)	0.78 (0.33-1.88)	0.582
Site of metastasis (visceral vs. non-visceral)	0.54 (0.18-1.61)	0.267
TMB (High vs. Low)	1.08 (0.38-3.09)	0.88

308

309 Baseline ctDNA-related markers are associated with mTNBC patient

310 survival and treatment response

To further explore the value of ctDNA in predicting clinical outcomes in mTNBC, we 311 examined the association between the pre-treatment ctDNA-related markers (i.e., TMB, 312 MATH score, and ctDNA%) and PFS and the treatment response. Thus, we performed 313 314 Kaplan-Meier analyses of TMB, MATH score, ctDNA%, and PFS in patients with mTNBC. Although not statistically significant, TMB-high (≥ 2.63) patients tended to 315 have a shorter mPFS than the TMB-low (< 2.63) patients (5.87 months vs. 10.03 months, 316 P = 0.057) (Figure 4A). Meanwhile, patients with a higher MATH score (≥ 6.316) had 317 318 significantly shorter mPFS than patients with a lower MATH score (< 6.316) (5.67 months vs.11.27 months, P = 0.007) (Figure 4B). Moreover, the higher ctDNA% (\geq 319 0.05) patient group had a significantly shorter mPFS than the lower ctDNA% (< 0.05) 320

321 group (5.45 months *vs.* 12.17 months, P < 0.001) (Figure 4C). Patients with mTNBC 322 were categorized into the PD, SD, PR, and CR groups according to their response to 323 treatment. Further comparative analysis of baseline ctDNA parameters in different 324 treatment response groups revealed that TMB was progressively lower across the four 325 groups, showing a decreasing trend from the PD group to the CR group. Compared with 326 other treatment response groups, the PD group had a larger TMB (P = 0.032), greater 327 MATH score (P = 0.003), and higher ctDNA% (P = 0.002) (Figure 4D–F).



329 Figure 4. The baseline-ctDNA-derived TMB, MATH score, and ctDNA% were associated with the clinical 330 outcomes of patients with mTNBC. Higher TMB (≥ 2.63) (A), MATH score (≥ 6.316) (B), and ctDNA% (≥ 0.05) (C) were linked to a shorter PFS. The optimal cut-off values for TMB, MATH score, and ctDNA% were determined 331 332 using the R package "survminer". Comparison of TMB (D), MATH score (E), and ctDNA% (F) in patients with 333 different treatment responses (PD, SD, PR, or CR). CR, complete response; ctDNA, circulating tumor DNA; 334 ctDNA%, ctDNA fraction; mTNBC, metastatic triple-negative breast cancer; PFS, progression-free survival; PD, 335 progressive disease; PR, partial response; SD, stable disease; TMB, tumor mutational burden. A P-value < 0.05 was 336 used as a measure of statistical significance.

337

328

338 Dynamic changes in ctDNA are associated with treatment response of 339 patients with mTNBC

Figure 5A–D highlight the dynamic changes in ctDNA levels (i.e., mutations in 12 prognosis-relevant genes) and traditional tumor markers in each patient with PD (Patient 32), SD (Patient 31), PR (Patient 29), or CR (Patient 18). For instance in Patient 32, the MAF of *MYC* ctDNA increased significantly and was accompanied by increased

CA125 and CA153 levels and decreased CEA levels at the time of disease progression 344 (Figure 5A). Figure 5B–D shows evidence of ctDNA mutations in Patient 31 (BTG2, 345 ARID4B, CD22, H3F3A, HLA-B, MCL1, MYC, RSPO2), Patient 29 (BTG2, ARID4B, 346 H3F3A, HLA-B, MCL1, MYC), and Patient 18 (BTG2, ARID4B, H3F3A, HLA-B, 347 SGK1); their mutational rates dropped to the lowest level during the best response to 348 treatment and rose again during progression. CA125 levels varied in line with treatment 349 response and progression but no similar fluctuations were observed for CA153 and 350 CEA. However, compared with the traditional tumor markers, dynamic changes in 351 ctDNA mutations seemed to better mirror treatment-induced changes in tumor size. We 352 therefore analyzed the correlation between the levels of serum tumor markers and tumor 353 size on computed tomography (CT) scans during treatment (Figure 5E). We found that 354 tumor size positively correlated with the MATH score (R = 0.24, P = 0.014) and ctDNA% 355 356 (R = 0.3, P = 0.002), but not CEA, CA125, or CA153 levels. There were also strong positive correlations among the three ctDNA-related markers, TMB, MATH score, and 357 ctDNA%. Moreover, the dynamic changes in ctDNA status may predict the prognosis 358 of mTNBC. Kaplan-Meier analysis found that patients who remained ctDNA+ during 359 dynamic monitoring had a shorter PFS than those who did not (3.90 months vs. 6.10 360 months, P = 0.135) (Figure 5F); however, this difference did not achieve statistical 361 significance, most likely due to the limited sample size. 362



Figure 5. Dynamic ctDNA changes in patients with mTNBC. (A-D) Dynamic changes in tumor size were 364 365 observed using computed tomography (CT) scans and the conventional tumor markers CEA, CA125, and CA153 366 (left side) or the VAF/copy number of 12 prognosis-relevant genes (right side) in four patients who each had a 367 different best treatment response: PD (Patient 32), SD (Patient 31), PR (Patient 29), and CR (Patient 18). (E) The 368 correlation between tumor size (measured using CT scans) and conventional tumor markers (CEA, CA125, CA153) 369 or ctDNA parameters (TMB, MATH score, ctDNA%). Blue: positive correlation; red: negative correlation (the 370 stronger the correlation, the darker the color). (F) Patients with a ctDNA+ status across all time points (All positive) 371 tended to have a shorter PFS than those who were ctDNA- at least once during the process of dynamic monitoring (Other). CR, complete response; ctDNA, circulating tumor DNA; ctDNA-, ctDNA negative; ctDNA+, ctDNA 372 373 positive; ctDNA%, ctDNA fraction; mTNBC, metastatic triple-negative breast cancer; PFS, progression-free 374 survival; PD, progressive disease; PR, partial response; SD, stable disease; TMB, tumor mutational burden; VAF, variant allelic frequency. A P-value < 0.05 was used as a measure of statistical significance. 375

376

363

377 **Discussion**

Since the advent of precision medicine, liquid biopsies have become more widely 378 utilized in the clinical management of cancer. In recent years, ctDNA has become the 379 focus of extensive research as a predictive biomarker of tumor progression and/or 380 381 treatment response. Several studies have explored the promising applications of ctDNA in breast cancer. For example, some researchers have investigated the longitudinal 382 dynamics of ctDNA in the treatment monitoring of metastatic breast cancer, while 383 others have studied the prognostic and predictive value of ctDNA during neoadjuvant 384 chemotherapy for TNBC(Cavallone et al., 2020; Gerratana et al., 2021; Ortolan et al., 385 2021; Riva et al., 2017). However, the application of ctDNA in monitoring mTNBC is 386 rare in clinical practice. 387

In the current study, we performed targeted, capture-based NGS (with a 457-gene 388 panel) on 139 plasma samples obtained by liquid biopsy from 70 patients with mTNBC. 389 390 Thirteen paired tumor tissues were also analyzed to verify if ctDNA could be a feasible alternative to tumor-tissue-derived tDNA. This study demonstrated how a ctDNA-391 based platform could reliably reveal mutational profiles, stably predict the prognosis, 392 and consistently monitor the treatment response of patients with mTNBC. This study 393 also resolved the uncertainty of some current studies regarding the value of ctDNA and 394 provided clear ctDNA-related predictive markers for mTNBC patients. By evaluating 395 the mutational landscape of mTNBC in the Chinese population using ctDNA analysis, 396 we showed that the most frequently mutated genes were TP53, PIK3CA, ARID1A, and 397 398 KMT2C, and the most frequent CNV was detected in HLA-C, HLA-A, HLA-B, and HLA-DRB1 (Figure 2A). These genes play significant roles in the tumorigenesis, progression, 399 invasion, and metastasis of breast cancer. In the homogeneous population, the most 400 common mutations detected in tumor tissue were TP53, followed by PIK3CA, KMT2C, 401 and PTEN; however, the top-ranking CNVs were found in different genes to those 402 403 identified in a previous report: E2F3, IRS2, CCNE1, EGFR, NFIB, CCND1, and MYB(Jiang et al., 2019). This difference may be due to the fact that the plasma-derived 404 ctDNA contains smaller fragments than those that are typically found in tissue-derived 405 tDNA. Meanwhile, compared with the results of other ctDNA identification studies, the 406 distribution of frequent variants in the TNBC cohort was overall consistent(Davis et al., 407

2020; Rong et al., 2020; Wang et al., 2021). In the study by Chae et al., the concordance 408 between all ctDNA- and tDNA-derived genes was also similar to that in our study 409 (91.0%–94.2% vs. 98.75%)(Chae et al., 2017) (Figure 2B). The authors reported that 410 411 the ctDNA-based assay had a high specificity, with a diagnostic accuracy of up to 80%. Although the mutation frequency of tDNA was higher than that of ctDNA in our study, 412 the number of mutations detected in both types of DNA was similar. In addition, we 413 detected 37 specific mutations in each of the ctDNA and tDNA groups, demonstrating 414 the complementarity of blood-derived ctDNA and tissue-derived tDNA. Moreover, 415 compared with tumor tissue analysis, ctDNA assays only require a small blood sample, 416 can capture a variety of mutations (including SNVs and CNVs), and provide 417 information on spatial tumor heterogeneity. 418

Using NGS, we identified 12 prognosis-relevant mutated genes, which were 419 420 associated with the shorter PFS of patients with mTNBC (Supplementary Figure 3). Most of the 12 genes have been linked to breast cancer by previous studies. For instance, 421 the aberrant expression of KMT2C (low expression) and ARID4B (high expression) 422 contribute to the poor prognosis of patients with ER-positive breast cancer(Sato & 423 Akimoto, 2017; J. Zhang et al., 2021). However, previous studies have shown that the 424 upregulated expression of BTG2 and CD22 were associated with improved survival, 425 which is not in agreement with our current findings(Mascia et al., 2022; Y. J. Zhang et 426 al., 2013); this may be due to the low number of patients included in this study. TGFB1, 427 SGK1, RSPO2, and MCL1 are implicated in the invasion, migration, growth, autophagy, 428 and progression of TNBC, while RSPO2 and MCL1 overexpression is associated with 429 shorter survival rates in patients with TNBC(Coussy et al., 2017; S. Kim, Lee, Jeon, 430 Nam, & Lee, 2015; Yang et al., 2014; Zhu et al., 2020). 431

As a common driver of breast cancer, *MYC* amplification plays a role in emerging or acquired chemotherapy resistance during neoadjuvant treatment of TNBC and can also synergize with *MCL1* amplification to maintain chemoresistance(Lee et al., 2017). *HLA-B*, a major histocompatibility complex (MHC) class I molecule, is involved in immunosurveillance against tumors and its expression is correlated with the invasiveness and prognosis of breast cancer(Concha, Esteban, Cabrera, Ruiz-Cabello,

438 & Garrido, 1991). To date, there have been no reports of an association between *H3F3A* 439 or *KYAT3* and breast cancer. Previously, *H3F3A* was identified as a driver gene in 440 glioma, and its overexpression is linked to shorter survival rates and disease progression 441 in lung cancer(Felker & Broniscer, 2020; Park et al., 2016). Thus, although the 442 associations between of some of the 12 mutated genes identified in our study and cancer 443 are known, their roles in the prognosis of mTNBC need to be further defined.

We also explored the value of ctDNA status as a biomarker for predicting the 444 prognosis and monitoring the treatment response of patients with mTNBC. We found 445 that a ctDNA+ status was associated with a worse treatment response (Figure 3B, C). 446 In addition, we showed that the ctDNA status at baseline could potentially discriminate 447 between mTNBC patients with a high or low lesion load (Figure 3D), predict their 448 prognosis (Figure 3E), and act as an independent prognostic factor (Table 3). This 449 450 indicates that the ctDNA status, associated with the presence of the 12 prognosisrelevant mutated genes, may be a good guide to the prediction of clinical outcomes and 451 the clinical management of TNBC. We further explored the optimal cut-off values for 452 the ctDNA-based TMB, MATH score, and ctDNA% parameters at baseline using 453 Kaplan–Meier analysis. A high MATH score (≥ 6.316) and high ctDNA% (≥ 0.05) were 454 associated with a significantly shorter PFS (Figure 4B, C) and may therefore be related 455 to the tumor burden of mTNBC. A study reported that most ctDNA fragments originate 456 from metastases and not early-stage cancer, suggesting that ctDNA-based NGS may be 457 more suitable for the analysis of metastatic tumors (Vandekerkhove et al., 2017). Unlike 458 ctDNA%, the MATH score represents tumor heterogeneity. A previous study found that 459 TNBC was associated with a higher MATH score(Ma, Jiang, Liu, Liu, & Shao, 2017). 460 Moreover, patients with higher MATH ("Clinical practice guidelines for the use of 461 tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the 462 American Society of Clinical Oncology," 1996)scores tend to have more diverse tumor 463 cell clones and may be more prone to drug resistance and progression(McDonald et al., 464 2019; Mroz & Rocco, 2013). Thus, the MATH score could also potentially be used as 465 a biomarker for mTNBC prognosis. 466

467 Breast cancer is a highly heterogeneous and dynamic disease; therefore, longitudinal

monitoring and management are necessary(Garcia-Murillas et al., 2015). The predictive 468 value of ctDNA has prompted further exploration of its feasibility in the dynamic 469 monitoring of the efficacy of neoadjuvant therapy for breast cancer, and in predicting 470 471 the occurrence of distal metastasis and drug resistance(Cavallone et al., 2020; Darrigues et al., 2021; Wang et al., 2021). Here, we monitored ctDNA to track the dynamic 472 changes in the 12 identified prognosis-related genes during the treatment of patients 473 with mTNBC. The results showed that the elimination of these mutations or the 474 reduction in the mutation rate of these genes was often associated with a better 475 treatment response. Conversely, reappearance of these mutations at a later time point or 476 an increase in their mutation rate signaled disease progression. Thus, we showed that 477 the analysis of ctDNA was sensitive and accurately reflected the treatment response and 478 disease status of patients with mTNBC in a timely manner. Conventional tumor markers 479 480 have been widely used in clinical cancer management for some time("Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on 481 May 17, 1996 by the American Society of Clinical Oncology," 1996). We found that, 482 the serum CEA and CA153 levels contradicted the treatment response of Patient 31 at 483 the mid-treatment time point (Figure 5B). The elevation of conventional tumor markers 484 could indicate changes in the tumor and could be interpreted as an early warning of 485 disease progression or pseudo-progression. However, this pseudo-progression or 486 "tumor marker spike" is actually caused by extensive neoplastic cell necrosis induced 487 by anti-tumor therapy. This phenomenon is observed in up to 30% of patients who 488 respond to treatment(Seregni, Coli, & Mazzucca, 2004). NGS-mediated ctDNA 489 detection identifies hundreds or thousands of mutations. Even if individual mutations 490 were the result of a "ctDNA spike" (similar to a "tumor marker spike"), other mutations 491 could be relied upon to accurately signal treatment efficacy. Moreover, we observed 492 positive correlations between treatment response and MATH score and ctDNA%, but 493 not the CEA, CA125, and CA153 levels (Figure 5E). Hence, compared with 494 conventional tumor markers, ctDNA dynamics may better reflect treatment response 495 496 and progression in mTNBC.

497

Several limitations exist in our study. First, this was a single-center study with a small

sample size. Second, the relatively short median follow-up duration was insufficient for capturing a clinically significant association between ctDNA mutations and overall survival. Third, several patients were lost to follow-up, which may have biased the results. Fourth, the potential influence of different treatment lines and regimens was not evaluated; nevertheless, no differences were found in survival based on these factors. Finally, compared with whole-exome sequencing or whole-genome sequencing, NGS with a panel of 457 selected genes, as used in our study, provided limited mutation data.

506 **Conclusions**

ctDNA profiling is a good alternative to tumor tissue sequencing and provides valuable 507 insights into the mutational landscape of mTNBC. Furthermore, our study addressed 508 509 the value of ctDNA in predicting the prognosis and monitoring the treatment response of patients with mTNBC. The results revealed that higher ctDNA%, MATH score, TMB, 510 ctDNA+ status, and mutation rate were associated with a poor prognosis and a worse 511 treatment response in mTNBC. Moreover, the longitudinal monitoring of genetic 512 biomarkers in ctDNA was more sensitive and accurate for discerning treatment 513 response or progression than traditional tumor markers such as CEA, CA125, and 514 CA153. Taken together, these findings will contribute to a better understanding of 515 ctDNA in mTNBC and may facilitate the development of a more accurate and non-516 517 invasive clinical strategy for managing patients with this condition. However, larger clinical trials are necessary to validate our results. 518

519

520 Additional information

521 **Competing interests**

522 The authors declare no potential conflicts of interest.

523 Funding

Funder	Grant No.	Author
National Natural Science Foundation of	81902713	Huihui Li
China		
Natural Science Foundation of Shandong	ZR2019LZL018	Jinming Yu
Province		
	22	

Breast Disease Research Fund of Shandong	YXH2020ZX066	Huihui Li
Provincial Medical Association		
Start-up Fund of Shandong Cancer Hospital	2020-PYB10	Huihui Li
Beijing Science and Technology Innovation	KC2021-ZZ-0010-1	Huihui Li
Fund		

524 Acknowledgments

525 We sincerely thank the support of Yongsheng Wang, Pengfei Qiu, Binbin Cong, Peng 526 Chen, Yanbing Liu, Chunjian Wang, Zhaopeng Zhang, Tong Zhao, Xiao Sun, Zhiyong Yu, Zhijun Huo, Xinzhao Wang, Shubin Song, Liang Zhang, Zhaoyun Liu, Fukai Wang, 527 Chao Li, Xiang Song, Wenshu Zuo, Hui Fu, Meizhu Zheng, Ben Yang, Chao Han, Qian 528 Shao, Xijun Liu, Jinzhi Wang, Wei Wang, Fengxiang Li, Yun Zhao, Linlin Wang, 529 530 Bingjie Fan, Bing Zou, Zhenhua Gao, Xiangjiao Meng, Liyang Jiang, Zhengqiang Yang and Peng Xie. We also thank Liwen Bianji (Edanz) (www.liwenbianji.cn) for editing a 531 draft of this manuscript. 532 **Ethics** 533 Human subjects: The study was approved by the Ethics Committee of Shandong Cancer 534 Hospital and Institute (approval number: SDTHEC201806003) that collection of 535 536 information, tumor tissues and blood samples within the ethical limitition of the patients,

- and conducted according to the Declaration of Helsinki. Written informed consent was
- 538 obtained from all patients.

539 Data Availability

The raw sequence data generated during the current study have been deposited in the China National Genomics Data Center (<u>https://ngdc.cncb.ac.cn/gsa-human/</u>). The data under accession HRA002598 will be available on 27 June 2024 and are also available from the corresponding author upon reasonable request.

544

545 **References**

Alix-Panabières, C., & Pantel, K. (2016). Clinical Applications of Circulating Tumor
Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov, 6(5), 479491. doi:10.1158/2159-8290.Cd-15-1483

549 Asante, D. B., Calapre, L., Ziman, M., Meniawy, T. M., & Gray, E. S. (2020). Liquid

550	biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for
551	prime time? Cancer Lett, 468, 59-71. doi:10.1016/j.canlet.2019.10.014
552	Barroso-Sousa, R., Forman, J., Collier, K., Weber, Z. T., Jammihal, T. R., Kao, K. Z.,
553	Tolaney, S. M. (2022). Multidimensional Molecular Profiling of Metastatic
554	Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO
555	Precis Oncol, 6, e2100413. doi:10.1200/po.21.00413
556	Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua,
557	S. A., Brown, P. H. (2015). Comprehensive genomic analysis identifies
558	novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res,
559	21(7), 1688-1698. doi:10.1158/1078-0432.Ccr-14-0432
560	Campos-Carrillo, A., Weitzel, J. N., Sahoo, P., Rockne, R., Mokhnatkin, J. V., Murtaza,
561	M., Slavin, T. P. (2020). Circulating tumor DNA as an early cancer detection
562	tool. Pharmacol Ther, 207, 107458. doi:10.1016/j.pharmthera.2019.107458
563	Cavallone, L., Aguilar-Mahecha, A., Lafleur, J., Brousse, S., Aldamry, M., Roseshter,
564	T., Basik, M. (2020). Prognostic and predictive value of circulating tumor
565	DNA during neoadjuvant chemotherapy for triple negative breast cancer. Sci
566	Rep, 10(1), 14704. doi:10.1038/s41598-020-71236-y
567	Chae, Y. K., Davis, A. A., Jain, S., Santa-Maria, C., Flaum, L., Beaubier, N.,
568	Cristofanilli, M. (2017). Concordance of Genomic Alterations by Next-
569	Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in
570	Breast Cancer. Mol Cancer Ther, 16(7), 1412-1420. doi:10.1158/1535-
571	7163.Mct-17-0061
572	Chae, Y. K., & Oh, M. S. (2019). Detection of Minimal Residual Disease Using ctDNA
573	in Lung Cancer: Current Evidence and Future Directions. J Thorac Oncol, 14(1),
574	16-24. doi:10.1016/j.jtho.2018.09.022
575	Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R.,
576	Frampton, G. M. (2017). Analysis of 100,000 human cancer genomes reveals
577	the landscape of tumor mutational burden. Genome Med, 9(1), 34.
578	doi:10.1186/s13073-017-0424-2
579	Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018). fastp: an ultra-fast all-in-one FASTQ

24

580 preprocessor. Bioinformatics, 34(17), i884-i890.

581 doi:10.1093/bioinformatics/bty560

- Chen, S., Zhou, Y., Chen, Y., Huang, T., Liao, W., Xu, Y., . . . Gu, J. (2019). Gencore:
 an efficient tool to generate consensus reads for error suppressing and duplicate
 removing of NGS data. BMC Bioinformatics, 20(Suppl 23), 606.
 doi:10.1186/s12859-019-3280-9
- Chopra, N., Tovey, H., Pearson, A., Cutts, R., Toms, C., Proszek, P., . . . Turner, N. C.
 (2020). Homologous recombination DNA repair deficiency and PARP
 inhibition activity in primary triple negative breast cancer. Nat Commun, 11(1),
 2662. doi:10.1038/s41467-020-16142-7
- Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer.
 Adopted on May 17, 1996 by the American Society of Clinical Oncology.
 (1996). J Clin Oncol, 14(10), 2843-2877. doi:10.1200/jco.1996.14.10.2843
- Collier, K. A., Asad, S., Tallman, D., Jenison, J., Rajkovic, A., Mardis, E. R., . . . Stover,
 D. G. (2021). Association of 17q22 Amplicon Via Cell-Free DNA With
 Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer.
 JCO Precis Oncol, 5. doi:10.1200/po.21.00104
- Concha, A., Esteban, F., Cabrera, T., Ruiz-Cabello, F., & Garrido, F. (1991). Tumor
 aggressiveness and MHC class I and II antigens in laryngeal and breast cancer.
 Semin Cancer Biol, 2(1), 47-54.
- Coussy, F., Lallemand, F., Vacher, S., Schnitzler, A., Chemlali, W., Caly, M., ... Bièche,
 I. (2017). Clinical value of R-spondins in triple-negative and metaplastic breast
 cancers. Br J Cancer, 116(12), 1595-1603. doi:10.1038/bjc.2017.131
- Darrigues, L., Pierga, J. Y., Bernard-Tessier, A., Bièche, I., Silveira, A. B., Michel,
 M., . . . Bidard, F. C. (2021). Circulating tumor DNA as a dynamic biomarker
 of response to palbociclib and fulvestrant in metastatic breast cancer patients.
 Breast Cancer Res, 23(1), 31. doi:10.1186/s13058-021-01411-0
- Davis, A. A., Jacob, S., Gerratana, L., Shah, A. N., Wehbe, F., Katam, N., . . .
 Cristofanilli, M. (2020). Landscape of circulating tumour DNA in metastatic
 breast cancer. EBioMedicine, 58, 102914. doi:10.1016/j.ebiom.2020.102914

- Dawson, S. J., Tsui, D. W., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S. F., . . .
- 611 Rosenfeld, N. (2013). Analysis of circulating tumor DNA to monitor metastatic
- breast cancer. N Engl J Med, 368(13), 1199-1209.
 doi:10.1056/NEJMoa1213261
- Diaz, L. A., Jr., & Bardelli, A. (2014). Liquid biopsies: genotyping circulating tumor
 DNA. J Clin Oncol, 32(6), 579-586. doi:10.1200/jco.2012.45.2011
- Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., ...
- 617 Verweij, J. (2009). New response evaluation criteria in solid tumours: revised
 618 RECIST guideline (version 1.1). Eur J Cancer, 45(2), 228-247.
 619 doi:10.1016/j.ejca.2008.10.026
- Felker, J., & Broniscer, A. (2020). Improving long-term survival in diffuse intrinsic
 pontine glioma. Expert Rev Neurother, 20(7), 647-658.
 doi:10.1080/14737175.2020.1775584
- Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010). Triple-negative breast cancer.
 N Engl J Med, 363(20), 1938-1948. doi:10.1056/NEJMra1001389
- Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., . . .
 Turner, N. C. (2015). Mutation tracking in circulating tumor DNA predicts
 relapse in early breast cancer. Sci Transl Med, 7(302), 302ra133.
 doi:10.1126/scitranslmed.aab0021
- Gerratana, L., Davis, A. A., Zhang, Q., Basile, D., Rossi, G., Strickland, K., . . .
 Cristofanilli, M. (2021). Longitudinal Dynamics of Circulating Tumor Cells and
 Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer.
 JCO Precis Oncol, 5, 943-952. doi:10.1200/po.20.00345
- Jiang, Y. Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., . . . Shao, Z. M. (2019). Genomic
 and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes
 and Treatment Strategies. Cancer Cell, 35(3), 428-440.e425.
 doi:10.1016/j.ccell.2019.02.001
- Kim, H., Kim, Y. J., Park, D., Park, W. Y., Choi, D. H., Park, W., . . . Kim, N. (2021).
 Dynamics of circulating tumor DNA during postoperative radiotherapy in
 patients with residual triple-negative breast cancer following neoadjuvant

- chemotherapy: a prospective observational study. Breast Cancer Res Treat,
 189(1), 167-175. doi:10.1007/s10549-021-06296-3
- Kim, S., Lee, J., Jeon, M., Nam, S. J., & Lee, J. E. (2015). Elevated TGF-β1 and -β2
 expression accelerates the epithelial to mesenchymal transition in triplenegative breast cancer cells. Cytokine, 75(1), 151-158.
 doi:10.1016/j.cyto.2015.05.020
- Lee, K. M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L.,
 Hutchinson, K. E., . . . Arteaga, C. L. (2017). MYC and MCL1 Cooperatively
 Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of
 Mitochondrial Oxidative Phosphorylation. Cell Metab, 26(4), 633-647.e637.
 doi:10.1016/j.cmet.2017.09.009
- Li, H., & Durbin, R. (2009). Fast and accurate short read alignment with BurrowsWheeler transform. Bioinformatics, 25(14), 1754-1760.
 doi:10.1093/bioinformatics/btp324
- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., . . . Durbin, R.
 (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics,
 25(16), 2078-2079. doi:10.1093/bioinformatics/btp352
- Li, J., Lupat, R., Amarasinghe, K. C., Thompson, E. R., Doyle, M. A., Ryland, G. L., ...
 Gorringe, K. L. (2012). CONTRA: copy number analysis for targeted
 resequencing. Bioinformatics, 28(10), 1307-1313.
 doi:10.1093/bioinformatics/bts146
- Li, X., Yang, J., Peng, L., Sahin, A. A., Huo, L., Ward, K. C., . . . Meisel, J. L. (2017).
 Triple-negative breast cancer has worse overall survival and cause-specific
 survival than non-triple-negative breast cancer. Breast Cancer Res Treat, 161(2),
 279-287. doi:10.1007/s10549-016-4059-6
- Lin, P. H., Wang, M. Y., Lo, C., Tsai, L. W., Yen, T. C., Huang, T. Y., . . . Huang, C. S.
 (2021). Circulating Tumor DNA as a Predictive Marker of Recurrence for
 Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy.
 Front Oncol, 11, 736769. doi:10.3389/fonc.2021.736769
- Ma, D., Jiang, Y. Z., Liu, X. Y., Liu, Y. R., & Shao, Z. M. (2017). Clinical and molecular

- 670 relevance of mutant-allele tumor heterogeneity in breast cancer. Breast Cancer
 671 Res Treat, 162(1), 39-48. doi:10.1007/s10549-017-4113-z
- Madic, J., Kiialainen, A., Bidard, F. C., Birzele, F., Ramey, G., Leroy, Q., . . . Lebofsky,
 R. (2015). Circulating tumor DNA and circulating tumor cells in metastatic
 triple negative breast cancer patients. Int J Cancer, 136(9), 2158-2165.
 doi:10.1002/ijc.29265
- Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R., ...
 Arpino, G. (2012). Clinical and biologic features of triple-negative breast
 cancers in a large cohort of patients with long-term follow-up. Breast Cancer
 Res Treat, 136(3), 795-804. doi:10.1007/s10549-012-2315-y
- Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S., Moore, K. L., Joshi, S. S., ...
 Catenacci, D. V. T. (2019). Circulating Tumor DNA Sequencing Analysis of
 Gastroesophageal Adenocarcinoma. Clin Cancer Res, 25(23), 7098-7112.
 doi:10.1158/1078-0432.Ccr-19-1704
- Mascia, F., Mazo, I., Alterovitz, W. L., Karagiannis, K., Wu, W. W., Shen, R. F., ...
 Rao, V. A. (2022). In search of autophagy biomarkers in breast cancer: Receptor
 status and drug agnostic transcriptional changes during autophagy flux in cell
 lines. PLoS One, 17(1), e0262134. doi:10.1371/journal.pone.0262134
- McDonald, K. A., Kawaguchi, T., Qi, Q., Peng, X., Asaoka, M., Young, J., . . . Takabe,
 K. (2019). Tumor Heterogeneity Correlates with Less Immune Response and
 Worse Survival in Breast Cancer Patients. Ann Surg Oncol, 26(7), 2191-2199.
 doi:10.1245/s10434-019-07338-3
- Mroz, E. A., & Rocco, J. W. (2013). MATH, a novel measure of intratumor genetic
 heterogeneity, is high in poor-outcome classes of head and neck squamous cell
 carcinoma. Oral Oncol, 49(3), 211-215.
 doi:10.1016/j.oraloncology.2012.09.007
- Murtaza, M., Dawson, S. J., Tsui, D. W., Gale, D., Forshew, T., Piskorz, A. M., . . .
 Rosenfeld, N. (2013). Non-invasive analysis of acquired resistance to cancer
 therapy by sequencing of plasma DNA. Nature, 497(7447), 108-112.
 doi:10.1038/nature12065

- 700 Ortolan, E., Appierto, V., Silvestri, M., Miceli, R., Veneroni, S., Folli, S., ... Di Cosimo,
- 701 S. (2021). Blood-based genomics of triple-negative breast cancer progression in
- patients treated with neoadjuvant chemotherapy. ESMO Open, 6(2), 100086.
 doi:10.1016/j.esmoop.2021.100086
- Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., ... Silvestris,
 F. (2018). Liquid biopsy of cancer: a multimodal diagnostic tool in clinical
 oncology. Ther Adv Med Oncol, 10, 1758835918794630.
 doi:10.1177/1758835918794630
- Park, S. M., Choi, E. Y., Bae, M., Kim, S., Park, J. B., Yoo, H., . . . Kim, I. H. (2016).
 Histone variant H3F3A promotes lung cancer cell migration through intronic
 regulation. Nat Commun, 7, 12914. doi:10.1038/ncomms12914
- Perou, C. M. (2011). Molecular stratification of triple-negative breast cancers.
 Oncologist, 16 Suppl 1, 61-70. doi:10.1634/theoncologist.2011-S1-61
- Poulet, G., Massias, J., & Taly, V. (2019). Liquid Biopsy: General Concepts. Acta Cytol,
 63(6), 449-455. doi:10.1159/000499337
- Riva, F., Bidard, F. C., Houy, A., Saliou, A., Madic, J., Rampanou, A., . . . Pierga, J. Y.
 (2017). Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant
 Chemotherapy in Triple-Negative Breast Cancer. Clin Chem, 63(3), 691-699.
 doi:10.1373/clinchem.2016.262337
- Rong, G., Yi, Z., Ma, F., Guan, Y., Xu, Y., Li, L., & Xu, B. (2020). Mutational
 characteristics determined using circulating tumor DNA analysis in triplenegative breast cancer patients with distant metastasis. Cancer Commun (Lond),
 40(12), 738-742. doi:10.1002/cac2.12102
- Sato, K., & Akimoto, K. (2017). Expression Levels of KMT2C and SLC20A1
 Identified by Information-theoretical Analysis Are Powerful Prognostic
 Biomarkers in Estrogen Receptor-positive Breast Cancer. Clin Breast Cancer,
 17(3), e135-e142. doi:10.1016/j.clbc.2016.11.005
- Seregni, E., Coli, A., & Mazzucca, N. (2004). Circulating tumour markers in breast
 cancer. Eur J Nucl Med Mol Imaging, 31 Suppl 1, S15-22. doi:10.1007/s00259004-1523-z

730	Stover, D. G., Parsons, H. A., Ha, G., Freeman, S. S., Barry, W. T., Guo, H.,
731	Adalsteinsson, V. A. (2018). Association of Cell-Free DNA Tumor Fraction and
732	Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative
733	Breast Cancer. J Clin Oncol, 36(6), 543-553. doi:10.1200/jco.2017.76.0033
734	Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray,
735	F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence
736	and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin,
737	71(3), 209-249. doi:10.3322/caac.21660
738	Swarup, V., & Rajeswari, M. R. (2007). Circulating (cell-free) nucleic acidsa
739	promising, non-invasive tool for early detection of several human diseases.
740	FEBS Lett, 581(5), 795-799. doi:10.1016/j.febslet.2007.01.051
741	Vandekerkhove, G., Todenhöfer, T., Annala, M., Struss, W. J., Wong, A., Beja, K.,
742	Wyatt, A. W. (2017). Circulating Tumor DNA Reveals Clinically Actionable
743	Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res, 23(21), 6487-
744	6497. doi:10.1158/1078-0432.Ccr-17-1140
745	Wang, Y., Lin, L., Li, L., Wen, J., Chi, Y., Hao, R., Wang, O. (2021). Genetic
746	landscape of breast cancer and mutation tracking with circulating tumor DNA
747	in Chinese women. Aging (Albany NY), 13(8), 11860-11876.
748	doi:10.18632/aging.202888
749	Weber, Z. T., Collier, K. A., Tallman, D., Forman, J., Shukla, S., Asad, S., Stover,
750	D. G. (2021). Modeling clonal structure over narrow time frames via circulating
751	tumor DNA in metastatic breast cancer. Genome Med, 13(1), 89.
752	doi:10.1186/s13073-021-00895-x
753	Wongchenko, M. J., Kim, S. B., Saura, C., Oliveira, M., Lipson, D., Kennedy, M.,
754	Dent, R. (2020). Circulating Tumor DNA and Biomarker Analyses From the
755	LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for
756	Metastatic Triple-Negative Breast Cancer. JCO Precis Oncol, 4, 1012-1024.
757	doi:10.1200/po.19.00396
758	Yang, L., Perez, A. A., Fujie, S., Warden, C., Li, J., Wang, Y., Yen, Y. (2014). Wnt
759	modulates MCL1 to control cell survival in triple negative breast cancer. BMC

760	Cancer, 14, 124. doi:10.1186/1471-2407-14-124
761	Zhang, J., Hou, S., You, Z., Li, G., Xu, S., Li, X., Pang, D. (2021). Expression and
762	prognostic values of ARID family members in breast cancer. Aging (Albany
763	NY), 13(4), 5621-5637. doi:10.18632/aging.202489
764	Zhang, Y. J., Wei, L., Liu, M., Li, J., Zheng, Y. Q., Gao, Y., & Li, X. R. (2013). BTG2
765	inhibits the proliferation, invasion, and apoptosis of MDA-MB-231 triple-
766	negative breast cancer cells. Tumour Biol, 34(3), 1605-1613.
767	doi:10.1007/s13277-013-0691-5
768	Zhu, R., Yang, G., Cao, Z., Shen, K., Zheng, L., Xiao, J., Zhang, T. (2020). The
769	prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer
770	therapy: a rising star. Ther Adv Med Oncol, 12, 1758835920940946.
771	doi:10.1177/1758835920940946
772	
773	
774	
775	
776	
777	
778	
779	
780	
781	
782	
783	
784	
785	
786	
787	
788	
789	

Supplement table 1. The list of 457 genes detected in this study.

-										
ABL1	BRCA1	CDKN2C	ERBB3	GABRA6	IRF4	MAPK8IP1	NOTCH4	POLE	RPA3	TEK
ACVR1B	BRCA2	CEBPA	ERBB4	GAGE1	IRS2	MCL1	NPM1	POLQ	RPL22	TENT5C
ACVR2A	BRD4	CHEK1	ERCC2	GALNT12	ITK	MDM2	NRAS	PPARG	RPL5	TET1
AJUBA	BRIP1	CHEK2	ERCC3	GATA1	JAK1	MDM4	NRG1	PPM1D	RPTOR	TET2
AKT1	BTG1	CIC	ERCC4	GATA2	JAK2	MECOM	NSD1	PPP2R1A	RUNX1	TGFB1
AKT2	BTG2	CREBBP	ERCC5	GATA3	JAK3	MED12	NSD2	PPP2R2A	SDHA	TGFBR2
AKT3	BTK	CRIPAK	ERG	GATA4	JUN	MEF2B	NSD3	PRDM1	SDHB	TIPARP
ALK	BTLA	CRKL	ERRFI1	GATA6	KDM5A	MEN1	NT5C2	PRF1	SDHC	TLR4
ALOX12B	EMSY	CSF1R	ESR1	GID4 (C17orf39)	KDM5C	MERTK	NT5E	PRKAR1A	SDHD	TNF
AMER1	CALR	CSF3R	ETV1	GNA11	KDM6A	MET	NTRK1	PRKCI	SETBP1	TNFAIP3
APC	CARD11	CTAG2	EZH2	GNA13	KDR	MGMT	NTRK2	PRX	SETD2	TNFRSF14
AR	CASP8	CTCF	FANCA	GNAQ	KEAP1	MITF	NTRK3	PTCH1	SF3B1	TNFRSF18
ARAF	CBFB	CTLA4	FANCC	GNAS	KEL	MKNK1	P2RY8	PTEN	SGK1	TNFRSF4
ARFRP1	CBL	CTNNA1	FANCG	GREM1	KIT	MLH1	PALB2	PTK6	SH2D1A	TNFSF11
ARHGAP35	CCND1	CTNNB1	FANCL	GRM3	KITLG	MLH3	PRKN	PTPN11	SIK1	TNFSF14
ARHGEF12	CCND2	CUL3	FANCM	GSK3B	KLHL6	MPL	PARP1	PTPRD	SIN3A	TNFSF18
ARID1A	CCND3	CUL4A	FAS	H3F3A	KMT2A	MRE11	PARP2	PTPRK	SLAMF7	TNFSF4
ARID2	CCNE1	CXCR4	FBXW7	H3F3C	KMT2B	MSH2	PARP3	PTPRO	SMAD2	TOP1
ARID5B	CD160	CYP17A1	FGF10	HAVCR2	KMT2C	MSH3	PAX5	PTPRT	SMAD4	TP53
ASXL1	CD22	DAXX	FGF12	HDAC1	KMT2D	MSH6	PBRM1	QKI	SMARCA4	TSC1
ATM	CD244	DDR1	FGF14	HDAC2	KRAS	MST1R	PCBP1	RAC1	SMARCB1	TSC2
ATR	CD274	DDR2	FGF19	HDAC3	LAG3	MTAP	PCNA	RAD21	SMC1A	TSHR
ATRX	CD276	DICER1	FGF23	HDAC6	LCK	MTOR	PDCD1	RAD50	SMC3	TSHZ2
AURKA	CD28	DIS3	FGF3	HGF	LEF1	MUTYH	PDCD1LG2	RAD51	SMO	TSHZ3
AURKB	CD38	DNMT3A	FGF4	HIST1H1C	LIFR	MYC	PDGFRA	RAD51B	SNCAIP	TYRO3
AXIN1	CD48	DOT1L	FGF6	HIST1H2BD	LIMK1	MYCL	PDGFRB	RAD51C	SOCS1	U2AF1
AXIN2	CD69	EED	FGFR1	HNF1A	LRRK2	MYCN	PDK1	RAD51D	SOX17	USP9X
AXL	CD70	EGFR	FGFR2	HRAS	LTK	MYD88	PHF6	RAD52	SOX2	VEGFA
B2M	CD79A	EGR3	FGFR3	HSD3B1	LYN	NAV3	PHOX2B	RAD54L	SOX9	VEGFB
B4GALT3	CD79B	EIF4A2	FGFR4	ICOS	MAF	NBN	PIGF	RAF1	SPATA2	VEZF1
BAGE	CD80	ELF3	FH	ICOSLG	MAGEA1	NCOA4	PIK3C2B	RARA	SPEN	VHL
BAP1	CD86	EOMES	FLCN	ID3	MAGEA12	NCOR1	PIK3C2G	RB1	SPOP	VTCN1
BARD1	CDC73	EP300	FLT1	IDH1	MAGEA3	NEK11	PIK3CA	RBM10	SRC	WT1
BCL2	CDH1	EPCAM	FLT3	IDH2	MAGEA4	NF1	PIK3CB	RECQL	STAG2	XPO1
BCL2L1	CDK12	EPHA1	FLT4	IGF1R	MAGEC2	NF2	PIK3CD	RECQL4	STAT3	XRCC2
BCL2L2	CDK4	EPHA2	FOXA1	IGF2	MAP2K1	NFE2L2	PIK3CG	REL	STK11	ZNF217
BCL6	CDK6	EPHA3	FOXA2	IKBKE	MAP2K2	NFE2L3	PIK3R1	RET	SUFU	ZNF703
BCOR	CDK8	EPHB1	FOXL2	IKZF1	MAP2K4	NFKBIA	PIK3R2	RICTOR	SYK	
BCORL1	CDKN1A	EPHB4	FOXO3	IL7R	MAP3K1	NKX2-1	PIM1	RNF43	TAF1	
BLM	CDKN1B	EPHB6	FOXP1	INPP4B	MAP3K13	NOTCH1	PMS1	ROS1	TAS2R38	
BMPR1A	CDKN2A	EPPK1	FRK	INSR	MAPK1	NOTCH2	PMS2	RPA1	TBL1XR1	
BRAF	CDKN2B	ERBB2	FUBP1	IRF2	MAPK11	NOTCH3	POLD1	RPA2	TBX3	



Supplementary Figure 1



Supplementary Figure 1. (A) Kaplan–Meier analysis of PFS in all patients with mTNBC. (B) Kaplan–Meier analysis of PFS in patients with different lines of treatment. (C–H) Kaplan–Meier analysis of PFS in patients treated with distinct treatment regimens. GP, gemcitabine- and platinum-based treatment; IC, immunotherapy plus chemotherapy; mTNBC, metastatic triple-negative breast cancer; P, platinum-based treatment; PFS, progression-free survival; T, taxane-based treatment; TP, taxane- and platinum-based treatment. A *P*-value < 0.05 was used as a measure of statistical significance.</p>

798



799

800 Supplementary Figure 2. Comparison of mutation frequency between ctDNA and tissue. The mutation 801 frequency in ctDNA was significantly lower than that in tissues (P < 0.001). ctDNA, circulating tumor DNA. A P-

value < 0.05 was used as a measure of statistical significance.



Supplementary Figure 3. Kaplan–Meier analysis of the PFS of 12 prognosis-relevant mutated genes in patients
with mTNBC. Patients with mutated *HLA-B* (A), *MYC* (B), *CD22* (C), *BTG2* (D), *KMT2C* (E), *TGFB1* (F), *MCL1*(G), *KYAT3* (H), *SGK1* (I), *H3F3A* (J), *ARID4B* (K), or *RSPO2* (L) had a significantly shorter PFS. Gain = copy
number gain; mTNBC, metastatic triple-negative breast cancer patients; Mut, mutated; PFS, progression-free
survival. WT, wild type. A *P*-value < 0.05 was used as a measure of statistical significance.

803